The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Nov 27

PMID 39598531

Authors

Xinyu Wu

Huihua Xiong

Affiliations

Soon will be listed here.

Abstract

Given the high prevalence of breast cancer and the diverse genetic backgrounds of patients, a growing body of research emphasizes the importance of pharmacogenetic-based pharmacokinetic analysis in optimizing treatment outcomes. The treatment of breast cancer involves multiple drugs whose metabolism and efficacy are influenced by individual genetic variations. Genetic polymorphisms in drug-metabolizing enzymes and transport proteins are crucial in the regulation of pharmacokinetics. Our review aims to investigate the opportunities and challenges of pharmacogenomic-based pharmacokinetic analysis as a precision medicine tool in breast cancer management.

References

Tremmel R, Zhou Y, Schwab M, Lauschke V . Structural variation of the coding and non-coding human pharmacogenome. NPJ Genom Med. 2023; 8(1):24. PMC: 10491600. DOI: 10.1038/s41525-023-00371-y. View

Haidar C, Crews K, Hoffman J, Relling M, Caudle K . Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. Annu Rev Genomics Hum Genet. 2022; 23:449-473. PMC: 9483991. DOI: 10.1146/annurev-genom-111621-102737. View

Boso V, Herrero M, Santaballa A, Palomar L, Megias J, de la Cueva H . SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics. 2014; 15(15):1845-58. DOI: 10.2217/pgs.14.127. View

Turijan-Espinoza E, Ruiz-Rodriguez V, Uresti-Rivera E, Martinez-Leija E, Zermeno-Nava J, Guel-Panola A . Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients. Cancer Chemother Pharmacol. 2021; 87(6):843-853. DOI: 10.1007/s00280-021-04244-y. View

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z . Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27(11):1904-1909. DOI: 10.1038/s41591-021-01562-9. View

Richard S, Selle F, Lotz J, Khalil A, Gligorov J, Soares D . Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc. 2016; 88 Suppl 1:565-77. DOI: 10.1590/0001-3765201620150178. View

Lonning P, Pfister C, Martoni A, Zamagni C . Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003; 30(4 Suppl 14):23-32. DOI: 10.1016/s0093-7754(03)00305-1. View

Slavin T, Banks K, Chudova D, Oxnard G, Odegaard J, Nagy R . Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018; :JCO1800328. PMC: 6286162. DOI: 10.1200/JCO.18.00328. View

Busby J, Mills K, Zhang S, Liberante F, Cardwell C . Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res. 2018; 20(1):4. PMC: 5775583. DOI: 10.1186/s13058-017-0928-0. View

10.

Kim H, Im S, Keam B, Ham H, Lee K, Kim T . ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2014; 106(1):86-93. PMC: 4317776. DOI: 10.1111/cas.12560. View

11.

Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V . Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006; 79(6):570-80. DOI: 10.1016/j.clpt.2006.02.003. View

12.

Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y . Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020; 50(10):1242-1250. DOI: 10.1080/00498254.2020.1755909. View

13.

Wang H, Ma X, Zhang B, Zhang Y, Han N, Wei L . Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. Asia Pac J Clin Oncol. 2021; 18(2):e148-e153. PMC: 9290498. DOI: 10.1111/ajco.13571. View

14.

Zhao J, Zhang H, Lei T, Liu J, Zhang S, Wu N . Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer. Cancer Biol Med. 2020; 17(4):1014-1025. PMC: 7721095. DOI: 10.20892/j.issn.2095-3941.2020.0157. View

15.

Chen S, Li X, Li Y, He X, Bryant M, Qin X . The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023; 197(1):69-78. PMC: 10734604. DOI: 10.1093/toxsci/kfad099. View

16.

Huddart R, Fohner A, Whirl-Carrillo M, Wojcik G, Gignoux C, Popejoy A . Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. Clin Pharmacol Ther. 2018; 105(5):1256-1262. PMC: 6465129. DOI: 10.1002/cpt.1322. View

17.

Caudle K, Dunnenberger H, Freimuth R, Peterson J, Burlison J, Whirl-Carrillo M . Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2016; 19(2):215-223. PMC: 5253119. DOI: 10.1038/gim.2016.87. View

18.

Osborne C . Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339(22):1609-18. DOI: 10.1056/NEJM199811263392207. View

19.

Hertz D, Roy S, Motsinger-Reif A, Drobish A, CLARK L, McLeod H . CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013; 24(6):1472-8. PMC: 3660078. DOI: 10.1093/annonc/mdt018. View

20.

Sawyer M, Pituskin E, Damaraju S, Bies R, Vos L, Prado C . A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clin Breast Cancer. 2015; 16(2):139-44.e1-3. DOI: 10.1016/j.clbc.2015.09.006. View